Avita has recently struck deals with other distributors in the UK, France, Japan and South Korea. It is currently negotiating with additional companies in key markets with the ultimate goal of further penetrating its burn and wound care products globally. Among the products the company manufactures is its line of ReCell devices, which allow physicians to quickly regenerate skin by using a small sample of the patient's skin. Avita shares closed up 5 cents, or 3.2 percent, to $1.60 on the over-the-counter market.